Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PESETA: Progesterone Added to EDP + Mitotane in Advanced Adrenocortical Carcinoma
2024-520160-34-00Phase 2Authorised
- Sponsor
- ASST Spedali Civili di Brescia
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in adrenal cancer (ACC) comparing EDP + mitotane + Megace with EDP + mitotane + placebo (2 arms). Primary endpoint: Objective response rate. Planned start Jan 2025; status: authorised.
02
Drugs
megestrol
03
Conditions
adrenal cancer (ACC)
Beyond the preview
Go deeper on 2024-520160-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520160-34-00.